DiaMedica Therapeutics
DiaMedica Therapeutics43About
What does DiaMedica Therapeutics do?
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies that reduce ischemia for patients with serious vascular diseases. Their initial focus is on preeclampsia, fetal growth restriction, and acute ischemic stroke, aiming to reverse ischemic injury and improve patient outcomes. The company is advancing patient care through a novel approach with their lead drug candidate, DM199.
What is DiaMedica Therapeutics's revenue?
StartupHub estimates DiaMedica Therapeutics's annual revenue at $4.2M (range $1.5M to $12.6M, 34% confidence), based on comparable companies in the sector.
What is DiaMedica Therapeutics's valuation?
StartupHub estimates DiaMedica Therapeutics's effective valuation at $8.1M (range $3.2M to $15.2M, 54% confidence), based on comparable companies in the sector.
How much funding has DiaMedica Therapeutics raised?
DiaMedica Therapeutics has raised a total of $30M in funding. The most recent round on record is Private Placement.
Where is DiaMedica Therapeutics headquartered?
DiaMedica Therapeutics is headquartered in Minneapolis, United States.
When was DiaMedica Therapeutics founded?
DiaMedica Therapeutics was founded in 2000.
What industry does DiaMedica Therapeutics operate in?
DiaMedica Therapeutics operates in Biotechnology, Healthcare, Pharmaceuticals.
No comments yet. Be the first to share your take.